Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine Effect on Circadian Rhythm in Moderate Alzheimer's Disease
NCT01181921Phase 4Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2011
- Primary completion
- Jun 2011
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of galantamine in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Primary endpoint: Change From Baseline in Sleep/Wake Patterns as Measured by Actigraph at 12 weeks. Started May 2011; status: terminated.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01181921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01181921.